{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:07:02Z","timestamp":1784696822022,"version":"3.55.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The association among metabolic dysfunction, antidiabetic drugs, and asthma has attracted increasing attention in recent years. However, the knowledge structure, dominant metabolic mechanisms, drug-related research hotspots, and clinical translational evidence in this interdisciplinary field remain insufficiently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted a bibliometric evidence-mapping and visualization analysis of research linking metabolic dysfunction, antidiabetic drugs, and asthma published between 2006 and 2025. Data were obtained from the Web of Science Core Collection, Scopus, and PubMed. Bibliometric and visualization methods were used to identify global research trends, major knowledge domains, thematic evolution, and emerging translational frontiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1, 502 records from the Web of Science Core Collection, 6, 710 records from Scopus, and 38 PubMed-indexed clinical studies were included. Publication output showed an overall upward trend, with a marked increase in research attention after 2015. Keyword and clustering analyses indicated that obesity, insulin resistance, metabolic syndrome, inflammation, oxidative stress, adipokines, lung function, and airway hyperresponsiveness formed the dominant knowledge base of this field. In contrast, drug-related topics, including metformin, peroxisome proliferator-activated receptor \u03b3 agonists, glucagon-like peptide-1 receptor agonists, sodium\u2013glucose cotransporter 2 inhibitors, and dipeptidyl peptidase-4 inhibitors, gradually entered the research network but generally showed relatively limited centrality and uneven clinical evidence. Reference co-citation and burst analyses further suggested that recent research frontiers are shifting toward drug-related mechanisms, asthma exacerbations, and clinical outcome evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research in this field has evolved from early studies of metabolic comorbidity and inflammatory mechanisms toward drug-related mechanisms, asthma outcomes, and translational evidence. The dominant knowledge base is centered on obesity, insulin resistance, metabolic inflammation, oxidative stress, and airway dysfunction, whereas drug-specific evidence remains emerging and uneven across drug classes. Future studies should integrate large-scale clinical data, prospective cohorts, and randomized controlled trials to clarify whether selected antidiabetic drugs may modify asthma outcomes in metabolically defined asthma phenotypes. This study provides an evidence-mapping perspective for understanding the metabolic, pharmacological, and clinical translational links among metabolic dysfunction, antidiabetic drugs, and asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1883559","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:42:52Z","timestamp":1784695372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025"],"prefix":"10.3389","volume":"17","author":[{"given":"Rong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Nursing, Yantaishan Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery I, Yantaishan Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology I, Yantaishan Hospital","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.02.011","article-title":"Airway hyperresponsiveness in asthma: The role of the epithelium","volume":"153","author":"Bradding","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/mcp.0b013e32831da8fd","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"240088","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00390-6","article-title":"The aetiology and molecular landscape of insulin resistance","volume":"22","author":"James","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222819","article-title":"Association between asthma and type 2 diabetes in a Swedish adult population: a register-based cross-sectional study","volume":"80","author":"Mubanga","year":"2025","journal-title":"Thorax"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2174\/1573399814666180711114859","article-title":"Type 2 diabetes and asthma: Systematic review of the bidirectional relationship","volume":"15","author":"Rayner","year":"2019","journal-title":"Curr Diabetes Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202406-1166so","article-title":"Obesity-related asthma: A pathobiology-based overview of existing and emerging treatment approaches","volume":"210","author":"Althoff","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.004","article-title":"Obesity and asthma","volume":"141","author":"Peters","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0017ps","article-title":"Mechanisms of asthma in obesity. Pleiotropic aspects of obesity produce distinct asthma phenotypes","volume":"54","author":"Dixon","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.011","article-title":"Obesity and asthma","volume":"146","author":"Miethe","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.07.002","article-title":"Metabolic asthma: is there a link between obesity, diabetes, and asthma","volume":"34","author":"Perez","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.993406","article-title":"Airway smooth muscle function in asthma","volume":"13","author":"Xiong","year":"2022","journal-title":"Front Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109080","article-title":"Association between novel glucose-lowering drugs and risk of asthma: A network meta-analysis of cardiorenal outcome trials","volume":"183","author":"Wang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-s009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2414342","article-title":"Pioglitazone and asthma: a review of current evidence","volume":"62","author":"Barkas","year":"2025","journal-title":"J Asthma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","article-title":"Antidiabetic medication and asthma attacks","volume":"185","author":"Lee","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108197","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review","volume":"245","author":"Cooper","year":"2025","journal-title":"Respir Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251400536","article-title":"Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes","volume":"16","author":"Cheng","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2307\/1907187","article-title":"Nonparametric tests against trend","volume":"13","author":"Mann","year":"1945","journal-title":"Econometrica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1968.10480934","article-title":"Estimates of the regression coefficient based on Kendall's tau","volume":"63","author":"Sen","year":"1968","journal-title":"J Am Stat Assoc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2016.10.006","article-title":"Constructing bibliometric networks: A comparison between full and fractional counting","volume":"10","author":"Perianes-Rodriguez","year":"2016","journal-title":"J Informetrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108403","DOI":"10.1016\/j.rmed.2025.108403","article-title":"Metformin use is associated with reduced systemic steroid courses among pediatric asthma patients with diabetes or elevated blood glucose levels","volume":"248","author":"Ararat","year":"2025","journal-title":"Respir Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12931-021-01658-3","article-title":"Metformin use and respiratory outcomes in asthma-COPD overlap","volume":"22","author":"Wu","year":"2021","journal-title":"Respir Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.033","article-title":"A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma","volume":"140","author":"Kaler","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160257","article-title":"Evaluation of the PPAR-\u03b3 agonist pioglitazone in mild asthma: A double-blind randomized controlled trial","volume":"11","author":"Anderson","year":"2016","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12931-015-0303-6","article-title":"A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity","volume":"16","author":"Dixon","year":"2015","journal-title":"Respir Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587944-51","article-title":"Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease","volume":"87","author":"Byelan","year":"2015","journal-title":"Terapevticheskii arkhiv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.11.006","article-title":"Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial","volume":"104","author":"Richards","year":"2010","journal-title":"Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/clpt.2009.41","article-title":"Bronchodilatory effect of the PPAR-\u03b3 agonist rosiglitazone in smokers with asthma","volume":"86","author":"Spears","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"B33","first-page":"45","article-title":"The influence of insulin therapy on the course of acute exacerbation of bronchial asthma","volume-title":"Pathophysiology of Respiration","author":"Wytrychowski","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz053","article-title":"Impaired respiratory function in women with PCOS compared with matched controls from a population-based study","volume":"105","author":"Underdal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4037\/15597768-2008-2009","article-title":"Challenges to conducting multicenter clinical research: ten points to consider","volume":"19","author":"Irving","year":"2008","journal-title":"AACN Adv Crit Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200903-013st","article-title":"An official American Thoracic Society Workshop report: obesity and asthma","volume":"7","author":"Dixon","year":"2010","journal-title":"Proc Am Thorac Soc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.036","article-title":"Obesity and asthma: an association modified by age of asthma onset","volume":"127","author":"Holguin","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-023-00230-2","article-title":"Gaps and future directions in clinical research on obesity-related asthma","volume":"9","author":"Hudler","year":"2023","journal-title":"Pulm Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/jci200525102","article-title":"Inflammation, stress, and diabetes","volume":"115","author":"Wellen","year":"2005","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.10.004","article-title":"Obesity and severe asthma","volume":"68","author":"Tashiro","year":"2019","journal-title":"Allergol Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.09.025","article-title":"Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase","volume":"84","author":"Park","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u03baB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00442.2014","article-title":"NF-\u03baB-dependent airway inflammation triggers systemic insulin resistance","volume":"309","author":"Cyphert","year":"2015","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm.3423","article-title":"Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity","volume":"20","author":"Kim","year":"2014","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705630","article-title":"PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms","volume":"141","author":"Ward","year":"2004","journal-title":"Br J Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-022-00203-x","article-title":"Asthma exacerbations and glucagon-like peptide-1 receptor agonists: a review of the current evidence","volume":"8","author":"Kaplan","year":"2022","journal-title":"Pulm Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201506-385mg","article-title":"New insights in oxidant biology in asthma","author":"Erzurum","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/biom5031266","article-title":"NF-kappaB signaling in chronic inflammatory airway disease","volume":"5","author":"Schuliga","year":"2015","journal-title":"Biomolecules"},{"key":"B54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/164_2024_709","article-title":"Natural products for the management of asthma and COPD","volume":"287","author":"Liao","year":"2025","journal-title":"Handb Exp Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107918","article-title":"The interplay of plant-based antioxidants, inflammation, and clinical outcomes in asthma: a systematic review","volume":"236","author":"Ajaz","year":"2025","journal-title":"Respir Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-34","article-title":"Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study","volume":"10","author":"Rinne","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.201812-897oc","article-title":"Association of metformin initiation and risk of asthma exacerbation. A claims-based cohort study","volume":"16","author":"Wu","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"B58","doi-asserted-by":"publisher","first-page":"8211","DOI":"10.3390\/ijerph19138211","article-title":"Metformin and the development of asthma in patients with type 2 diabetes","volume":"19","author":"Yen","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9705604","DOI":"10.37766\/inplasy2020.4.0210","article-title":"Association of metformin use with asthma exacerbation in patients with concurrent asthma and diabetes: a systematic review and meta-analysis of observational studies","volume":"2020","author":"Wen","year":"2020","journal-title":"Can Respir J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/809164","article-title":"PPAR\u03b3 ligands regulate noncontractile and contractile functions of airway smooth muscle: implications for asthma therapy","volume":"2012","author":"Donovan","year":"2012","journal-title":"PPAR Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2014.128","article-title":"The PPAR\u03b3 agonist, rosiglitazone, attenuates airway inflammation and remodeling via heme oxygenase-1 in murine model of asthma","volume":"36","author":"Xu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-s010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202004-0993oc","article-title":"Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.05.002","article-title":"Association of novel antihyperglycemic drugs versus metformin with a decrease in asthma exacerbations","volume":"12","author":"Kimura","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108357","article-title":"SGLT2-inhibitors and asthma outcomes in type 2 diabetes: insights from a large multicenter study","volume":"248","author":"Alam","year":"2025","journal-title":"Respir Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221135320","article-title":"Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients","volume":"16","author":"Li","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.03.006","article-title":"Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review","volume":"139","author":"Bonaventura","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5444","article-title":"Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products","volume":"31","author":"Girman","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2200089","article-title":"Real-world evidence - where are we now","volume":"386","author":"Concato","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1883559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:43:08Z","timestamp":1784695388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1883559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":73,"alternative-id":["10.3389\/fendo.2026.1883559"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1883559","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1883559"}}